Alberto Mussetti
@albertomussetti.bsky.social
Director #HCT and #CART therapy Institut Català d'Oncologia, L' Hospitalet de Llobregat, Barcelona. #digitalmedicine #lymphoma #AI.
https://www.enciclopedia.cat/divulcat/Alberto-Mussetti
https://albertomussetti.substack.com/
https://www.enciclopedia.cat/divulcat/Alberto-Mussetti
https://albertomussetti.substack.com/
Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT url: ashpublications.org/blood/articl...
Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT
Key PointsTL1A-Ig+low-dose IL-2 pre-HSCT induces Treg expansion persisting early post-HSCT, diminishing GVHD, improving outcomes, and maintaining GVL.TL1A-
ashpublications.org
November 28, 2025 at 7:08 AM
Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT url: ashpublications.org/blood/articl...
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma url: ashpublications.org/bloodadvance...
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma
Key PointsMAESTRO-Pool is a highly sensitive, tumor-informed assay capable of detecting ctDNA early after chimeric antigen receptor T cells.Reduction of ct
ashpublications.org
November 18, 2025 at 11:16 PM
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma url: ashpublications.org/bloodadvance...
Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study url: ashpublications.org/bloodadvance...
Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study
Key PointsRoutine prophylaxis with LVT does not reduce the risk of any-grade or severe ICANS after CAR-T therapy for LBCL.LVT may induce deeper, early ICAH
ashpublications.org
November 18, 2025 at 11:14 PM
Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study url: ashpublications.org/bloodadvance...
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 | New England Journal of Medicine www.nejm.org/doi/full/10....
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 | NEJM
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases.
ANGPTL3 loss-of-function genetic variants are associated with decreased levels of
low-density lipoprotein cholest...
www.nejm.org
November 13, 2025 at 5:57 AM
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 | New England Journal of Medicine www.nejm.org/doi/full/10....
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
Artificial intelligence in hematology
In the last 2 years, the capabilities of artificial intelligence (AI) have progressed rapidly and are increasingly being integrated into hematology practic
ashpublications.org
November 6, 2025 at 10:55 PM
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma url: ashpublications.org/blood/articl...
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma
Key PointsWe developed a therapeutic cancer vaccine for MM against BCMA.Our findings revealed BCMA-specific immune response, providing the framework for it
ashpublications.org
November 6, 2025 at 10:54 PM
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma url: ashpublications.org/blood/articl...
Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia url: ashpublications.org/bloodadvance...
Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia
Key PointsOlder MSDs or young HIDs lead to similar survival in older patients with AML.Young HID is associated with less relapse, whereas older MSD is asso
ashpublications.org
November 4, 2025 at 8:46 PM
Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia url: ashpublications.org/bloodadvance...
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis url: ashpublications.org/bloodadvance...
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Key PointsReal-world effectiveness and safety outcomes in patients with R/R MCL treated with brexu-cel are similar to those of the ZUMA-2 trial.The benefit
ashpublications.org
October 29, 2025 at 12:48 AM
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis url: ashpublications.org/bloodadvance...
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy jitc.bmj.com/content/13/1...
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
Background Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). ...
jitc.bmj.com
October 12, 2025 at 5:23 PM
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy jitc.bmj.com/content/13/1...
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine DOI: 10.1056/NEJMc2508023
September 25, 2025 at 12:09 PM
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine DOI: 10.1056/NEJMc2508023
24th OCT 2025 - Barcelona
Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.
#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution
lnkd.in/dBDXnaSK
Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.
#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution
lnkd.in/dBDXnaSK
www.geth.es
September 18, 2025 at 3:09 PM
24th OCT 2025 - Barcelona
Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.
#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution
lnkd.in/dBDXnaSK
Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.
#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution
lnkd.in/dBDXnaSK
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT url: ashpublications.org/blood/articl...
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT
Key PointsAugmented CD47 expression on alloreactive donor T cells after HCT inhibits their phagocytosis by macrophages.Anti-CD47 treatment boosts phagocyto
ashpublications.org
September 11, 2025 at 8:34 PM
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT url: ashpublications.org/blood/articl...
Transformative Research in Cystic Fibrosis | New England Journal of Medicine www-nejm-org.sire.ub.edu/doi/full/10....
Shibboleth Authentication Request
www-nejm-org.sire.ub.edu
September 11, 2025 at 2:36 PM
Transformative Research in Cystic Fibrosis | New England Journal of Medicine www-nejm-org.sire.ub.edu/doi/full/10....
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies url: ashpublications.org/blood/articl...
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Key PointsWU-CART-007, an allogeneic anti-CD7 chimeric antigen receptor T cell, established a manageable safety profile at the RP2D of 900 × 106 cells.WU-C
ashpublications.org
September 4, 2025 at 8:08 PM
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies url: ashpublications.org/blood/articl...
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma url: ashpublications.org/blood/articl...
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
Key PointsDespite similar CAR T-cell dynamics, patients with SLE experienced less severe adverse events after CAR T-cell therapy than those with B-NHL.In p
ashpublications.org
August 28, 2025 at 8:11 PM
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma url: ashpublications.org/blood/articl...
